Phenotypic Drug Discovery

Phenotypic Drug Discovery: History, Evolution, Future;

Development and Validation of Disease Assays for Phenotypic Screening;

The Development and Use of Protein and Protein-affinity Libraries for Phenotypic Screening;

CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screening;

Contemporary Techniques for Target Deconvolution and Mode of Action Elucidation;

Artificial Intelligence as an Enabler for Phenotypic Drug Discovery;

Public–Private Partnerships to Advance Phenotypic Drug Discovery;

Identification of a Novel Class
of Small Molecules for Spinal Muscular Atrophy Through High-throughput Phenotypic Screening;

Antibody-based Phenotypic Screening – the Discovery of Oleclumab (MEDI9447);

Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia;

Phenotypic Screening for Drug Discovery in Tuberculosis;

Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers;

Phenotypic Screen Leads to Identification of Novel Posttranscriptional Regulation Machinery for HBV